News
Empowering the biopharma industry with field-leading foundation models.
Recent News
Press
|
May 20, 2026
Forbes: Inside Incyte’s $120 Million AI For Drug Development Deal
Forbes
Blog
|
June 10, 2026
Genesis Model Distillation
Blog
|
June 3, 2026
Zero-shot Pearl System Surpasses All Cofolding Models on OpenBind
Press Release
|
May 20, 2026
Incyte and Genesis Molecular AI Expand Collaboration
Press
|
December 2, 2025
Genesis Molecular AI Appoints Sergey Edunov as Senior Vice President of Foundation Models, Further Strengthening Leadership in Machine Learning
Business WIre
Blog
|
October 28, 2025
Introducing Pearl: The Next Generation Foundation Model for Drug Discovery
Press
|
October 28, 2025
Genesis Molecular AI Unveils Pearl
Business Wire
Press
|
October 28, 2025
Genesis says its new AI model bests AlphaFold 3
Endpoints News
Join Us
Opportunities in AI and Physics Research
Our molecular AI research team is pioneering new frameworks for drug discovery, at the intersection of multi-dimensional ML models and physical simulation. See opportunities in software engineering, machine learning and computation chemistry.
Software Engineering
Machine Learning
Computational Chemistry
